Audrey Nosbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Audrey Nosbaum has a total of 548 co-authors. Here are the top co-authors by number of shared publications:
- Jean-François Nicolas
CIRI (Centre International de Recherche en Infectiologie), INSERM, U1111, Univ Lyon, Université de Lyon 1, Ecole Normale Supérieure de Lyon, CNRS, UMR 5308, Lyon, France
51 shared publications - Frédéric Bérard
Claude Bernard University Lyon, Lyon, France
41 shared publications - Marc Vocanson
Centre International de Recherche en Infectiologie University of Lyon 1 and École Normale Supérieure de Lyon, Inserm U1111 Lyon France
17 shared publications - Aurore Rozières
Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Université Lyon 1, Inserm U1111, CNRS UMR5308, ENS de Lyon, 69007 Lyon, France
12 shared publications - Florence Hacard
Service d'Allergologie et d'Immunologie Clinique Hôpital Lyon‐Sud, Hospices Civils de Lyon, Inserm U1111 CIRI Pierre‐Bénite France
12 shared publications - Emmanuella Guenova
Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University , Linz
11 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 66 (5)
Quoi de neuf en allergologie pédiatrique en 2025 ?
- 30 September 2026
- Published by Elsevier in Revue Française d'Allergologie
- Vol. 66 (5)
Quoi de neuf en allergologie pédiatrique en 2025 ?
- Open Access
- 21 May 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI). In clinical trials, percent EASI improvement is used to compare study arms and measure treatment effect size/impact. In clinical practice, however, absolute EASI scores are used (especially in Europe), as they measure an individual’s disease state regardless of baseline severity. This post-hoc analysis assessed absolute EASI response – EASI≤7, ≤5, ≤3, and ≤1 – from the ADvocate trials to understand LEB efficacy in adults/adolescents with moderate-to-severe AD. Week-16 data from patients receiving LEB 250 mg Q2W (n=564) were compared with placebo (n=287). Across baseline moderate/severe/very severe EASI and baseline Investigator’s Global Assessment (IGA) 3/4, significantly higher percentages of patients receiving LEB than those receiving placebo achieved each absolute EASI response. Week--16 LEB EASI 75 responders (n=284) and per-protocol LEB non-responders (n=215) were assessed through week 52. Absolute EASI scores were generally low and stable among responders and reduced among non-responders. Overall, LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Results reflect clinically meaningful improvements that could help guide clinical practice.
- 21 May 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessAbsolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI). In clinical trials, percent EASI improvement is used to compare study arms and measure treatment effect size/impact. In clinical practice, however, absolute EASI scores are used (especially in Europe), as they measure an individual’s disease state regardless of baseline severity. This post-hoc analysis assessed absolute EASI response – EASI≤7, ≤5, ≤3, and ≤1 – from the ADvocate trials to understand LEB efficacy in adults/adolescents with moderate-to-severe AD. Week-16 data from patients receiving LEB 250 mg Q2W (n=564) were compared with placebo (n=287). Across baseline moderate/severe/very severe EASI and baseline Investigator’s Global Assessment (IGA) 3/4, significantly higher percentages of patients receiving LEB than those receiving placebo achieved each absolute EASI response. Week--16 LEB EASI 75 responders (n=284) and per-protocol LEB non-responders (n=215) were assessed through week 52. Absolute EASI scores were generally low and stable among responders and reduced among non-responders. Overall, LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Results reflect clinically meaningful improvements that could help guide clinical practice.
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle des lymphocytes cytotoxiques dans les hypersensibilités retardées cutanées
Les hypersensibilités retardées (HSR) cutanées sont hétérogènes, à la fois par la nature des mécanismes impliqués (allergiques versus non allergiques) mais aussi par les différents degrés de sévérité rencontrés. Seules les HSR allergiques sont dues à la présence de lymphocytes T (LT), mal caractérisés chez l'homme. Le but de ce travail est d'étudier la contribution des LT CD8 cytotoxiques dans le développement et la sévérité des HSR cutanées chez l'homme, à partir de deux pathologies fréquentes : les toxidermies aux béta lactamines et l'eczéma allergique de contact à la para-phénylènediamine (PPD). Tout d'abord, la présence de LT spécifiques de médicament au sein des toxidermies aux béta lactamines a été recherchée in vivo et in vitro. Nous avons montré que les HSR sévères étaient plus souvent d'origine allergique que les HSR bénignes. Nous avons ensuite caractérisé le rôle des LT CD8 dans les HSR allergiques. Dans les toxidermies bénignes à l'amoxicilline, l'étude de la cinétique de recrutement des LT au niveau cutané ainsi que l'analyse des LT spécifiques du sang circulant ont permis de mettre en évidence le rôle essentiel des LT CD8 cytotoxiques dans l'initiation de ces réactions. Ensuite, dans l'eczéma allergique de contact à la PPD, un recrutement épidermique précoce des LT CD8 associés à des marqueurs de cytotoxicité, a été retrouvé, corrélé avec la sévérité des lésions. Ces résultats ont été confortés par ceux obtenus dans un modèle pré-clinique d'HSR allergique à la PPD chez la souris. En conclusion, ce travail montre que les LT CD8 cytotoxiques pourraient être les principales cellules effectrices des HSR cutanées allergiques chez l'homme
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle des lymphocytes cytotoxiques dans les hypersensibilités retardées cutanées
Les hypersensibilités retardées (HSR) cutanées sont hétérogènes, à la fois par la nature des mécanismes impliqués (allergiques versus non allergiques) mais aussi par les différents degrés de sévérité rencontrés. Seules les HSR allergiques sont dues à la présence de lymphocytes T (LT), mal caractérisés chez l'homme. Le but de ce travail est d'étudier la contribution des LT CD8 cytotoxiques dans le développement et la sévérité des HSR cutanées chez l'homme, à partir de deux pathologies fréquentes : les toxidermies aux béta lactamines et l'eczéma allergique de contact à la para-phénylènediamine (PPD). Tout d'abord, la présence de LT spécifiques de médicament au sein des toxidermies aux béta lactamines a été recherchée in vivo et in vitro. Nous avons montré que les HSR sévères étaient plus souvent d'origine allergique que les HSR bénignes. Nous avons ensuite caractérisé le rôle des LT CD8 dans les HSR allergiques. Dans les toxidermies bénignes à l'amoxicilline, l'étude de la cinétique de recrutement des LT au niveau cutané ainsi que l'analyse des LT spécifiques du sang circulant ont permis de mettre en évidence le rôle essentiel des LT CD8 cytotoxiques dans l'initiation de ces réactions. Ensuite, dans l'eczéma allergique de contact à la PPD, un recrutement épidermique précoce des LT CD8 associés à des marqueurs de cytotoxicité, a été retrouvé, corrélé avec la sévérité des lésions. Ces résultats ont été confortés par ceux obtenus dans un modèle pré-clinique d'HSR allergique à la PPD chez la souris. En conclusion, ce travail montre que les LT CD8 cytotoxiques pourraient être les principales cellules effectrices des HSR cutanées allergiques chez l'homme
- 28 November 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (2) , 510-512.e1
Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Rα mAb
- 28 November 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (2) , 510-512.e1
Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Rα mAb
- Open Access
- 21 February 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9) , e772-e777
Atopic dermatitis in the French cohort CONSTANCES (PreDDA study): Focus on persistence and remission in adulthood
- 21 February 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (9) , e772-e777
Open AccessAtopic dermatitis in the French cohort CONSTANCES (PreDDA study): Focus on persistence and remission in adulthood
- Open Access
- 24 January 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (2) , 249-250
Methotrexate for atopic dermatitis: The right dosing and best‐performance administration route
- 24 January 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (2) , 249-250
Open AccessMethotrexate for atopic dermatitis: The right dosing and best‐performance administration route
- Open Access
- 12 December 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv41184
Effect of Therapeutic Patient Education in Adults with Atopic Dermatitis: Analysis of Efficacy and Treatment Needs
In the era of biological treatments and small molecules, this study assessed therapeutic patient education (TPE) in managing adult atopic dermatitis (AD), focusing on disease severity, quality of life, and the use of systemic treatments. This multicentre study included 260 adult AD patients, with 184 undergoing a full TPE programme and 76 control patients. Evaluations included disease severity, quality of life (DLQI), and systemic treatment use. The primary goal was to measure AD improvement, with secondary goals assessing DLQI score changes and systemic treatment use. AD severity improved in 64.7% of TPE patients vs 45.7% of controls (p = 0.008). The mean DLQI score dropped by 5.7 points in the TPE group vs 2.4 points in controls (p = 0.006). Additionally, 69.8% of TPE patients had a DLQI score ≤ 4/30 compared with 50% of controls (p = 0.025). Regarding therapeutics, 83.6% of patients naive to systemic treatment at inclusion were maintained exclusively under topical treatment vs 21.7% in the control group. The likelihood of needing systemic treatment was 66% in controls vs 6% in the TPE group. TPE enhances AD severity and quality of life, ensures better disease control, and reduces systemic treatment use, highlighting its importance in managing adult AD.
- 12 December 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv41184
Open AccessEffect of Therapeutic Patient Education in Adults with Atopic Dermatitis: Analysis of Efficacy and Treatment Needs
In the era of biological treatments and small molecules, this study assessed therapeutic patient education (TPE) in managing adult atopic dermatitis (AD), focusing on disease severity, quality of life, and the use of systemic treatments. This multicentre study included 260 adult AD patients, with 184 undergoing a full TPE programme and 76 control patients. Evaluations included disease severity, quality of life (DLQI), and systemic treatment use. The primary goal was to measure AD improvement, with secondary goals assessing DLQI score changes and systemic treatment use. AD severity improved in 64.7% of TPE patients vs 45.7% of controls (p = 0.008). The mean DLQI score dropped by 5.7 points in the TPE group vs 2.4 points in controls (p = 0.006). Additionally, 69.8% of TPE patients had a DLQI score ≤ 4/30 compared with 50% of controls (p = 0.025). Regarding therapeutics, 83.6% of patients naive to systemic treatment at inclusion were maintained exclusively under topical treatment vs 21.7% in the control group. The likelihood of needing systemic treatment was 66% in controls vs 6% in the TPE group. TPE enhances AD severity and quality of life, ensures better disease control, and reduces systemic treatment use, highlighting its importance in managing adult AD.
- Open Access
Glove-related contact dermatitis: diagnostic value of a repeated application test
Background: Gloves are frequently the cause of occupational hand dermatitis and are responsible for irritant (ICD) and allergic contact dermatitis (ACD). The diagnosis of ACD is based on patch tests to gloves (PTg), semi-open tests to gloves (SOg), and patch tests to glove allergens (PTal). Objective: The aim was to define the contribution of a glove repeated application test (GRAT) in the diagnosis strategy of glove-related contact dermatitis. Methods: This retrospective study included patients with hand eczema who wore gloves and who completed a GRAT in the context of allergological explorations. It consisted of applying a piece of the glove maintained by a non-adhesive strip during 10 consecutive nights on the same area of the anterior face of the forearm. Results: Ten patients were diagnosed with ACD to gloves. This diagnosis was made on positive SOg, PTg, GRAT and PTal for 2 patients, positive PTal and GRAT for 3 patients, positive SOg and GRAT for 2 patients, positive GRAT alone for 2 patients, positive PTal alone for 1 patient. The GRAT had better sensitivity than the other tests. Conclusion: GRAT seems useful in the diagnostic strategy of glove contact dermatitis and could be proposed when the diagnosis of glove-related contact dermatitis is suspected.
Open AccessGlove-related contact dermatitis: diagnostic value of a repeated application test
Background: Gloves are frequently the cause of occupational hand dermatitis and are responsible for irritant (ICD) and allergic contact dermatitis (ACD). The diagnosis of ACD is based on patch tests to gloves (PTg), semi-open tests to gloves (SOg), and patch tests to glove allergens (PTal). Objective: The aim was to define the contribution of a glove repeated application test (GRAT) in the diagnosis strategy of glove-related contact dermatitis. Methods: This retrospective study included patients with hand eczema who wore gloves and who completed a GRAT in the context of allergological explorations. It consisted of applying a piece of the glove maintained by a non-adhesive strip during 10 consecutive nights on the same area of the anterior face of the forearm. Results: Ten patients were diagnosed with ACD to gloves. This diagnosis was made on positive SOg, PTg, GRAT and PTal for 2 patients, positive PTal and GRAT for 3 patients, positive SOg and GRAT for 2 patients, positive GRAT alone for 2 patients, positive PTal alone for 1 patient. The GRAT had better sensitivity than the other tests. Conclusion: GRAT seems useful in the diagnostic strategy of glove contact dermatitis and could be proposed when the diagnosis of glove-related contact dermatitis is suspected.
- 14 July 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (11) , E1271-E1273
Use of therapeutic patient education tools for atopic dermatitis: A French national survey
- 14 July 2023
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (11) , E1271-E1273
Use of therapeutic patient education tools for atopic dermatitis: A French national survey
- 1 February 2023
- Published by JLE in European Journal Of Dermatology
- Vol. 33 (1) , 42-43
Allergic contact dermatitis to diclofenac gel due to propylene glycol sensitization: usefulness of repeated open application tests to determine safer alternatives
- 1 February 2023
- Published by JLE in European Journal Of Dermatology
- Vol. 33 (1) , 42-43
Allergic contact dermatitis to diclofenac gel due to propylene glycol sensitization: usefulness of repeated open application tests to determine safer alternatives